RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Clinical trials for RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Triple-Drug cocktail targets tough leukemia mutations
Disease control Recruiting nowThis study tests a combination of three drugs (azacitidine, venetoclax, and gilteritinib) in people with certain blood cancers that have a FLT3 mutation. The goal is to find the safest dose and see if the combo works better than standard treatments. The study includes adults whos…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New pill shows promise for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new daily pill, onvansertib, for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard therapies. The main goals are to find the safest dose and see if the drug can shrink or…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Metal detox may boost chemo in tough blood cancers
Disease control Recruiting nowThis early-stage study tests whether drugs that remove extra metals from the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. Researchers want to find the safest dose and see if lowering metal levels in blood…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for rare blood cancers: drug combo trial opens
Disease control Recruiting nowThis study tests a new drug called axatilimab, alone or with another drug (azacitidine), for people with advanced blood cancers like MPN, MPN/MDS overlap, or high-risk CMML. Axatilimab is an antibody that blocks a protein on white blood cells to slow cancer growth. The trial aims…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 19, 2026 11:59 UTC